Literature DB >> 9808589

Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer.

B R Blazar1, P A Taylor, R McElmurry, L Tian, A Panoskaltsis-Mortari, S Lam, C Lees, T Waldschmidt, D A Vallera.   

Abstract

Although in utero transplantation (IUT) has been shown to be effective in treating human severe combined immune deficiency (SCID), the relative merit of IUT as compared with postnatal bone marrow transplantation (BMT) for SCID is unknown. Therefore, comparative studies were undertaken in mice to determine the engraftment outcome in these two settings. Because T-cell depletion (TCD) reduces graft-versus-host disease (GVHD) severity but compromises alloengraftment, studies were performed with TCD or non-TCD BM and GVHD risk was assessed using a tissue scoring system and by the adoptive transfer of splenocytes from engrafted mice into secondary recipients. Non-SCID recipients received pre-BMT irradiation to simulate those circumstances in which conditioning is required for alloengraftment. IUT recipients of non-TCD and especially TCD BM cells in general had higher levels of donor T-cell and myeloid peripheral blood (PB) engraftment than nonconditioned SCID recipients. Increased TCD or non-TCD BM cell numbers in adult SCID recipients resulted in similar levels of PB engraftment as IUT recipients. However, under these conditions, mean GVHD scores were higher than in IUT recipients. The majority of adoptive transfer recipients of splenocytes from IUT recipients were GVHD-free, consistent with the in vitro evidence of tolerance to host alloantigens. Total body irradiation (TBI)-treated mice that had the highest engraftment had evidence of thymic damage as denoted by a higher proportion of thymic and splenic T cells with a memory phenotype as compared with IUT recipients. IUT mice had vigorous thymic reconstitution by 3 weeks of age. Our data indicate that IUT has a number of advantages as compared with postnatal BMT. Future studies examining the fine specificity of immunoreconstitution in IUT versus postnatal BMT are indicated.

Entities:  

Mesh:

Year:  1998        PMID: 9808589

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Early assessment of dosimetric and biological differences of total marrow irradiation versus total body irradiation in rodents.

Authors:  Susanta Hui; Yutaka Takahashi; Shernan G Holtan; Rezvan Azimi; Davis Seelig; Masashi Yagi; Jessie Ingvalson; Parham Alaei; Leslie Sharkey; Behiye Kodal; Nicholas Peterson; Carolyn Meyer; Lindsey Godin; Michael Ehrhardt; Guy Storme; Daohong Zhou; Angela Panoskaltsis-Mortari
Journal:  Radiother Oncol       Date:  2017-08-01       Impact factor: 6.280

2.  Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.

Authors:  Qing Ma; Dan Li; Roza Nurieva; Rebecca Patenia; Roland Bassett; Wei Cao; Andrei M Alekseev; Hong He; Jeffrey J Molldrem; Michael H Kroll; Richard E Champlin; George E Sale; Vahid Afshar-Kharghan
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-01       Impact factor: 5.742

3.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

4.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

5.  Club cell secretory protein improves survival in a murine obliterative bronchiolitis model.

Authors:  Christine Wendt; Kevin Tram; Andrew Price; Kristen England; Andrew Stiehm; Angela Panoskaltsis-Mortari
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

6.  Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Authors:  Marc O Johnson; Melissa M Wolf; Matthew Z Madden; Gabriela Andrejeva; Ayaka Sugiura; Diana C Contreras; Damian Maseda; Maria V Liberti; Katelyn Paz; Rigel J Kishton; Matthew E Johnson; Aguirre A de Cubas; Pingsheng Wu; Gongbo Li; Yongliang Zhang; Dawn C Newcomb; Andrew D Wells; Nicholas P Restifo; W Kimryn Rathmell; Jason W Locasale; Marco L Davila; Bruce R Blazar; Jeffrey C Rathmell
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

7.  CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation.

Authors:  William H Peranteau; Masayuki Endo; Obinna O Adibe; Aziz Merchant; Philip W Zoltick; Alan W Flake
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

8.  A new murine model for bronchiolitis obliterans post-bone marrow transplant.

Authors:  Angela Panoskaltsis-Mortari; Kevin V Tram; Andrew P Price; Christine H Wendt; Bruce R Blazar
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

9.  Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Jun Qi; Leo Luznik; Ivan Maillard; Kelli P MacDonald; Geoffrey R Hill; Jonathan S Serody; William J Murphy; Peter T Sage; Arlene H Sharpe; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; James E Bradner; Ari M Melnick; Bruce R Blazar
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

10.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.